Cancer Treatment Stock Approaches Key Buy Signal Ahead of Earnings

Zai Lab: A Promising Player in the Biopharmaceutical Sector

Zai Lab has emerged as a notable name in the biopharmaceutical industry, drawing attention from investors and analysts alike. The company, based in China, is currently being highlighted as one of the IBD 50 Growth Stocks To Watch due to its strong performance and potential for growth. Recent developments suggest that the stock is forming a handle in a base, which could signal a positive trend for future movements.

Zai Lab is set to report its second-quarter results before the market opens on Thursday. Management has expressed optimism, forecasting profitability by year-end. This outlook adds to the excitement surrounding the company, especially given its focus on addressing unmet needs in critical areas such as oncology, immunology, neuroscience, and infectious diseases.

The company has eight approved drugs in China and four approved by the U.S. Food and Drug Administration (FDA). Additionally, it has a robust pipeline of drug candidates. Among its top revenue-generating products are Vyvgart, Zejula, and Nuzyra. Vyvgart is used for treating autoimmune diseases, while Zejula plays a significant role in ovarian cancer treatment. Nuzyra is prescribed for bacterial infections, showcasing the company's diverse portfolio.

Stock Performance and Market Position

Zai Lab is part of the Medical-Biomedical/Biotech industry group, which ranks No. 20 among the 197 groups tracked by Investor's Business Daily. The stock is currently in an early-stage cup-with-handle base, with a buy point of 41.20 according to MarketSurge pattern recognition. The stock is approximately 6% below this entry point, indicating potential for recovery.

Shares have shown strength, trading above both their 21-day and 50-day exponential moving averages. After testing these levels on August 1, the stock has gained 48% so far this year. It has outperformed 94% of names in the IBD database, yet it still has a long way to go to reach its all-time high of 193.54, which was recorded on January 20, 2021.

The stock’s up/down volume ratio of 1.4 over the last 50 days indicates positive demand, although mutual funds have reduced their positions. In June, 203 funds owned shares, down from 230 in March. However, Fidelity Contrafund FCNTX increased its position to 1.4 million shares in June, up from 1.2 million in March. Additionally, management owns 5% of the shares, providing further incentive for the stock to perform well.

Financial Outlook and Analyst Expectations

Despite recent challenges, Zai Lab has shown signs of improvement. For its second quarter, the company is expected to post a loss of 42 cents per share, which is narrower than the loss of 80 cents per share in the same quarter a year earlier. In the first quarter, Zai Lab reported sales of $106.49 million, which fell short of expectations, but the loss of 40 cents per share was better than anticipated.

The company reaffirmed its full-year 2025 revenue guidance of $560 million to $590 million. Zai Lab President Josh Smiley emphasized the company’s progress in strengthening its financial position, noting a 20% year-over-year reduction in operating loss and a 25% year-over-year reduction in adjusted operating loss. These improvements position the company to achieve profitability in the fourth quarter of 2025.

Analysts now project a loss of $1.36 per share for full-year 2025, with a profit of 64 cents per share expected in 2026. Wall Street also anticipates accelerated sales growth, with second-quarter revenue projected to rise by 25% and increase by 81% over the next four quarters.

Conclusion

With a solid foundation, a diverse product portfolio, and a clear path toward profitability, Zai Lab presents an attractive opportunity for investors. As the company continues to navigate the complexities of the biopharmaceutical sector, its performance will be closely watched by market participants and analysts alike.